Ultragenyx Pharmaceutical Company Profile (NASDAQ:RARE)

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: RARE
CUSIP:

Key Metrics:

Previous Close: $68.58
50 Day Moving Average: $69.078
200 Day Moving Average: $63.614
52-Week Range: $46.52 - $117.12
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -11.39
P/E Growth: -0.380
Market Cap: $2.81B
Outstanding Shares: 39,435,000
Beta: 1.53

Profitability:

Return on Equity: -38.33%
Return on Assets: -36.33%

Debt:

Current Ratio: 14.40%
Quick Ratio: 14.40%

Additional Links:

Companies Related to Ultragenyx Pharmaceutical:

Consensus Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) (?)

Ratings Breakdown:	2 Hold Ratings, 14 Buy Ratings
Consensus Rating:	Buy (Score: 2.88)
Consensus Price Target:	$96.15 (35.54% upside)

Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Show:

Date	Firm	Action	Rating	Price Target
9/25/2016	HC Wainwright	Reiterated Rating	Buy	$102.00 -> $109.00
9/20/2016	Canaccord Genuity	Set Price Target	Buy	$120.00
9/20/2016	Leerink Swann	Reiterated Rating	Outperform	$85.00 -> $94.00
9/19/2016	Wedbush	Reiterated Rating	Outperform	$92.00
9/18/2016	Jefferies Group	Set Price Target	Buy	$109.00
9/14/2016	Credit Suisse Group AG	Reiterated Rating	Buy	$101.00
8/9/2016	Cowen and Company	Reiterated Rating	Buy
8/8/2016	JPMorgan Chase & Co.	Set Price Target	Buy	$110.00
8/9/2016	Piper Jaffray Cos.	Set Price Target	Buy	$70.00 -> $82.00
7/18/2016	Robert W. Baird	Reiterated Rating	Outperform	$85.00
6/28/2016	Bank of America Corp.	Initiated Coverage	Buy	$72.00
6/8/2016	Morgan Stanley	Reiterated Rating	Hold
6/8/2016	JMP Securities	Reiterated Rating	Buy	$80.00 -> $84.00
2/19/2016	Citigroup Inc.	Lower Price Target		$88.00 -> $67.00
2/9/2016	Sterne Agee CRT	Initiated Coverage	Buy
12/1/2015	Stifel Nicolaus	Initiated Coverage	Buy -> Buy	$125.00 -> $125.00
8/31/2015	Raymond James Financial Inc.	Initiated Coverage	Outperform	$125.00
7/13/2015	SunTrust Banks Inc.	Boost Price Target	Buy	$82.00 -> $119.00
3/30/2015	MLV & Co.	Initiated Coverage	Buy	$79.00
3/24/2015	CRT Capital	Initiated Coverage	Buy	$90.00

(Data available from 9/30/2014 forward)

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/7/2016
8/8/2016	Q2	($1.44)	($1.46)	View	N/A
5/9/2016	Q1	($1.29)	($1.35)	View	N/A
2/25/2016	Q4	($1.14)	($1.42)	View	Listen
11/9/2015	Q3	($0.87)	($1.03)	View	N/A
8/13/2015	Q215	($0.63)	($0.83)	View	Listen
5/11/2015	Q1 15	($0.54)	($0.63)	View	Listen
3/25/2015	Q414	($0.53)	($0.52)	View	Listen
11/10/2014	Q314	($0.46)	($0.50)	View	N/A
8/11/2014	Q214	($0.42)	($0.45)	View	N/A
5/12/2014	Q114	($0.37)	($0.85)	View	N/A
3/24/2014		($0.38)	($4.98)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Current Year EPS Consensus Estimate: $-5.96 EPS
Next Year EPS Consensus Estimate: $-6.23 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($1.38)	($1.13)	($1.26)
Q2 2016	4	($1.59)	($1.13)	($1.39)
Q3 2016	4	($1.55)	($1.51)	($1.53)
Q4 2016	4	($1.66)	($1.54)	($1.60)
Q1 2017	1	($1.70)	($1.70)	($1.70)
Q2 2017	1	($1.73)	($1.73)	($1.73)
Q3 2017	1	($1.67)	($1.67)	($1.67)
Q4 2017	1	($1.65)	($1.65)	($1.65)

(Data provided by Zacks Investment Research)

Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Insider Ownership Percentage: 10.10%
Institutional Ownership Percentage: 93.06%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/15/2016	Emil D Kakkis	CEO	Sell	20,000	$67.61	$1,352,200.00
7/21/2016	Sunil Agarwal	Insider	Sell	649	$52.68	$34,189.32
7/15/2016	Emil D Kakkis	CEO	Sell	20,000	$50.85	$1,017,000.00
6/20/2016	Sunil Agarwal	Insider	Sell	650	$54.16	$35,204.00
5/24/2016	Sunil Agarwal	Insider	Sell	650	$66.00	$42,900.00
5/16/2016	Emil D Kakkis	CEO	Sell	20,000	$59.95	$1,199,000.00
4/20/2016	Sunil Agarwal	Insider	Sell	649	$70.53	$45,773.97
4/15/2016	Emil D Kakkis	CEO	Sell	20,000	$70.33	$1,406,600.00
3/22/2016	Sunil Agarwal	Insider	Sell	650	$61.45	$39,942.50
2/22/2016	Sunil Agarwal	Insider	Sell	658	$63.48	$41,769.84
1/20/2016	Sunil Agarwal	insider	Sell	585	$72.83	$42,605.55
12/31/2015	Emil D. Kakkis	CEO	Sell	20,000	$114.52	$2,290,400.00
12/22/2015	Sunil Agarwal	Insider	Sell	498	$114.81	$57,175.38
12/18/2015	Theodore Alan Huizenga	insider	Sell	1,500	$110.55	$165,825.00
8/20/2015	Sunil Agarwal	insider	Sell	17,020	$111.18	$1,892,283.60
8/12/2015	Thomas Richard Kassberg	SVP	Sell	3,334	$109.70	$365,739.80
7/20/2015	Shalini Sharp	CFO	Sell	3,854	$131.95	$508,535.30
7/8/2015	Thomas Richard Kassberg	SVP	Sell	3,334	$102.12	$340,468.08
6/18/2015	Shalini Sharp	CFO	Sell	4,000	$96.08	$384,320.00
6/17/2015	Theodore Alan Huizenga	Insider	Sell	1,500	$94.80	$142,200.00
6/10/2015	Thomas Richard Kassberg	SVP	Sell	3,334	$88.19	$294,025.46
4/20/2015	Shalini Sharp	CFO	Sell	4,000	$62.23	$248,920.00
4/8/2015	Thomas Richard Kassberg	SVP	Sell	3,333	$58.02	$193,380.66
1/20/2015	Shalini Sharp	CFO	Sell	4,000	$51.24	$204,960.00
12/18/2014	Shalini Sharp	CFO	Sell	4,000	$44.82	$179,280.00
12/10/2014	Thomas Richard Kassberg	SVP	Sell	3,333	$40.22	$134,053.26
12/4/2014	William Aliski	Director	Sell	6,000	$42.16	$252,960.00
11/20/2014	Shalini Sharp	CFO	Sell	4,000	$44.07	$176,280.00
11/12/2014	Thomas Richard Kassberg	SVP	Sell	3,333	$41.85	$139,486.05
10/8/2014	Thomas Richard Kassberg	SVP	Sell	3,333	$53.26	$177,515.58
9/18/2014	Shalini Sharp	CFO	Sell	4,000	$56.00	$224,000.00
9/10/2014	Thomas Richard Kassberg	SVP	Sell	3,333	$54.82	$182,715.06
9/3/2014	Thomas Richard Kassberg	SVP	Sell	20,000	$53.91	$1,078,200.00
8/18/2014	Shalini Sharp	CFO	Sell	4,000	$53.97	$215,880.00
7/14/2014	Group Holdings (Sbs) Advis Tpg	Insider	Sell	488,820	$37.60	$18,379,632.00
1/31/2014	Fmr Llc	Insider	Buy	175,000	$21.00	$3,675,000.00
1/30/2014	Shalini Sharp	CFO	Buy	4,500	$21.00	$94,500.00
1/30/2014	Thomas Richard Kassberg	SVP	Buy	1,500	$21.00	$31,500.00
1/30/2014	William Aliski	Director	Buy	5,000	$21.00	$105,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Date	Headline
	Broker Roundup For Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) - The De Soto Edge (NASDAQ:RARE) desotoedge.com - September 29 at 6:53 PM
	Ultragenyx to Present at Leerink Partners Roundtable Series ... - GlobeNewswire (press release) (NASDAQ:RARE) globenewswire.com - September 27 at 6:52 PM
	Ultragenyx Pharmaceutical : to Present at Leerink Partners Roundtable Series (NASDAQ:RARE) www.4-traders.com - September 27 at 11:35 AM
	Ultragenyx to Present at Leerink Partners Roundtable Series (NASDAQ:RARE) www.publicnow.com - September 27 at 11:35 AM
	What is the Street Saying About Ultragenyx Pharmaceutical Inc ... - Frisco Fastball (NASDAQ:RARE) friscofastball.com - September 23 at 6:29 PM
	Stocks Showcasing Bullish Rally: Fiat Chrysler Automobiles (NYSE:FCAU), Ultragenyx Pharmaceutical (RARE ... - Street Wise Report (press release) (blog) (NASDAQ:RARE) streetwisereport.com - September 22 at 11:47 AM
	2 Sizzling Hot Biotechnology Stocks: Ultragenyx Pharmaceutical Inc. (RARE), Dynavax Technologies Corporation ... - The Independent Republic (NASDAQ:RARE) theindependentrepublic.com - September 22 at 11:47 AM
	Intraday Active Biotech Stocks News: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sarepta Therapeutics (NASDAQ ... - The Voice Registrar (NASDAQ:RARE) voiceregistrar.com - September 22 at 11:47 AM
	Jefferies Highlights Clinically Meaningful Data From Ultragenyx On KRN23 (NASDAQ:RARE) finance.yahoo.com - September 21 at 11:01 AM
	Volatile Mix Cap Mover- Healthways (NASDAQ:HWAY), Ultragenyx ... - Seneca Globe (NASDAQ:RARE) www.senecaglobe.com - September 20 at 12:13 PM
	Frontline Active Stocks in Broker Choice: Microsoft (NASDAQ:MSFT), Ultragenyx Pharmaceutical (RARE), Teradata ... - Street Wise Report (press release) (blog) (NASDAQ:RARE) streetwisereport.com - September 20 at 12:13 PM
	Why Sarepta Approval is Good News for BioMarin, Alexion (NASDAQ:RARE) blogs.barrons.com - September 20 at 12:13 PM
	Ultragenyx Pharmaceutical Inc. (RARE) Given a $109.00 Price ... - NewsDen (NASDAQ:RARE) newsden.net - September 19 at 6:53 PM
	Ultragenyx Pharma (RARE) Announces Positive Interim Data from ... - StreetInsider.com (NASDAQ:RARE) www.streetinsider.com - September 19 at 6:53 PM
	Ultragenyx Reports New Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia (NASDAQ:RARE) www.pipelinereview.com - September 19 at 11:32 AM
	Ultragenyx Pharma (RARE) Announces Positive Interim Data from KRN23 Phase 2 in TIO (NASDAQ:RARE) www.streetinsider.com - September 19 at 11:32 AM
	Ultragenyx:Pediatric Study Shows Reduction In Bone Disease&improvement In Growth (NASDAQ:RARE) www.rttnews.com - September 19 at 11:32 AM
	2:44 am Ultragenyx Pharma reports positive interim data from Phase 2 Study of KRN23 (NASDAQ:RARE) finance.yahoo.com - September 19 at 11:32 AM
	Ultragenyx Reports Positive Interim Data from Pediatric and Adult Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia (NASDAQ:RARE) finance.yahoo.com - September 19 at 11:32 AM
	Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia (NASDAQ:RARE) www.publicnow.com - September 18 at 6:29 PM
	Ultragenyx to Host Conference Call to Discuss KRN23 Data Presented at ASBMR 2016 Annual Meeting (NASDAQ:RARE) www.publicnow.com - September 16 at 10:33 AM
	Can Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Hit High Of $125? - Stocks Daily (NASDAQ:RARE) www.stocksdaily.net - September 15 at 7:03 PM
	Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Buy Rating ... - BNB Daily (blog) (NASDAQ:RARE) www.baseball-news-blog.com - September 15 at 7:03 PM
	Shares Higher in Current Session: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Post News (NASDAQ:RARE) www.kentuckypostnews.com - September 13 at 11:51 AM
	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earnings expectations - The Independent Republic (NASDAQ:RARE) theindependentrepublic.com - September 10 at 11:08 AM
	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE): What is the Sell-side Making of this Stock? - Post News (NASDAQ:RARE) www.kentuckypostnews.com - September 9 at 6:35 PM
	Can Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Surprise Analysts This Quarter? - Investor Newswire (NASDAQ:RARE) www.investornewswire.com - September 7 at 7:04 PM
	Ultragenyx to Present at Baird 2016 Global Healthcare Conference (NASDAQ:RARE) finance.yahoo.com - September 1 at 10:06 AM
	Discretionary Stocks Boost the Wells Fargo Growth Fund in YTD 2016 (NASDAQ:RARE) marketrealist.com - September 1 at 10:06 AM
	Ultragenyx Pharmaceutical Inc. (RARE) - Financial and Strategic SWOT Analysis Review - New Report Available (NASDAQ:RARE) www.live-pr.com - August 24 at 10:04 AM
	Ultragenyx Pharma (RARE) Announces Presentations Highlighting KRN23 at ASBMR Meeting (NASDAQ:RARE) www.streetinsider.com - August 23 at 11:32 AM
	Ultragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting (NASDAQ:RARE) www.publicnow.com - August 23 at 11:32 AM
	Can Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Meet Analysts Expectations? - Stocks Daily (NASDAQ:RARE) www.stocksdaily.net - August 20 at 6:40 PM
	ULTRAGENYX PHARMACEUTICAL INC. Financials (NASDAQ:RARE) finance.yahoo.com - August 17 at 7:23 PM
	Ultragenyx Pharmaceutical Inc (NASDAQ:RARE): We Bought The Stock At $57.40, Now Up Crazy 20% Quickly (NASDAQ:RARE) www.marketnewscall.com - August 12 at 10:14 AM
	Ultragenyx Pharmaceutical Inc (NASDAQ:RARE): We Bought The Stock At $57.40, Now Up Crazy 20% Quickly - Market News Call (NASDAQ:RARE) www.marketnewscall.com - August 11 at 7:34 PM
	Ultragenyx Pharmaceutical (RARE) Shares are Up 4.93% - Trade Calls (NASDAQ:RARE) www.tradecalls.org - August 9 at 7:20 PM
	Ultragenyx to Present at Upcoming Investor Conferences (NASDAQ:RARE) www.publicnow.com - August 9 at 10:15 AM
	EARNINGS SUMMARY: Details of Ultragenyx Pharmaceutical Inc Q2 Earnings Report (NASDAQ:RARE) www.rttnews.com - August 8 at 7:18 PM
	Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE) globenewswire.com - August 8 at 7:18 PM
	Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE) www.twst.com - August 8 at 7:18 PM
	Ultragenyx Pharmaceutical : reports 2Q loss (NASDAQ:RARE) www.4-traders.com - August 8 at 7:18 PM
	Ultragenyx reports 2Q loss (NASDAQ:RARE) sg.finance.yahoo.com - August 8 at 7:18 PM
	Q2 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close (NASDAQ:RARE) biz.yahoo.com - August 8 at 11:47 AM
	Ultragenyx Pharmaceutical Inc (NASDAQ:RARE): That’s How Our Subscribers Are Up 13% In One Week (NASDAQ:RARE) www.marketnewscall.com - August 4 at 10:12 AM
	ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events (NASDAQ:RARE) biz.yahoo.com - August 3 at 7:23 PM
	Ultragenyx Pharmaceutical Inc.: Ultragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE) www.twst.com - August 1 at 6:49 PM
	Here’s What We’re Looking For From Ultragenyx Pharmaceutical Inc (RARE) (NASDAQ:RARE) www.insidermonkey.com - August 1 at 6:49 PM
	Ultragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update (NASDAQ:RARE) www.publicnow.com - August 1 at 8:41 AM
	Here’s What We’re Looking For From Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) (NASDAQ:RARE) marketexclusive.com - July 30 at 9:52 AM